Alps Advisors Inc Point Biopharma Global Inc. Transaction History

Alps Advisors Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.67 - $9.71 $14,300 - $20,818	-2,144 Reduced 2.67%	78,042 $520,000
Q2 2023 Aug 14, 2023	BUY	$6.86 - $10.86 $72,599 - $114,931	10,583 Added 15.2%	80,186 $726,000
Q1 2023 May 10, 2023	SELL	$6.78 - $8.1 $13,621 - $16,272	-2,009 Reduced 2.81%	69,603 $506,000
Q4 2022 Feb 14, 2023	BUY	$5.72 - $9.78 $128,322 - $219,404	22,434 Added 45.62%	71,612 $522,000
Q3 2022 Nov 14, 2022	SELL	$7.24 - $10.31 $45,626 - $64,973	-6,302 Reduced 11.36%	49,178 $380,000
Q2 2022 Aug 11, 2022	BUY	$5.6 - $9.5 $310,688 - $527,060	55,480 New	55,480 $378,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.